Blog

Oct 20, 2024, 18:08

SOX with or without perioperative camrelizumab in locally advanced gastric cancer

Erman Akkus shared on X:

“Locally advanced gastric cancer.

Perioperative camrelizumab plus low-dose rivoceranib and S-1 and oxaliplatin (SOX) vs. SOX

3xneoadj-surgery-3xadjuvan->up to 1year camre/rivo

pCR: 18.3% vs 5%
Neoadjuvan grade ≥3 trAEs: 34% vs 17%.”

SOX with or without perioperative camrelizumab in locally advanced gastric cancer

Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)

Authors: Chen Li, Yantao Tian, Yanan Zheng, Fei Yuan, Zheng Shi, Lin Yang, Hao Chen, Lixin Jiang, Xixun Wang, Ping Zhao, Benyan Zhang, Zhenqiang Wang, Qun Zhao, Jianhong Dong, Changhong Lian, Sanrong Xu, Aimin Zhang, Zhichao Zheng, Kang Wang, Chengxue Dang, Dan Wu, Jian Chen, Yingwei Xue, Bo Liang, Xiangdong Cheng, Qian Wang, Luchuan Chen, Tao Xia, Heli Liu, Dazhi Xu, Jing Zhuang, Tao Wu, Xi Zhao, Wei Wu, Hongzhi Wang, Junsheng Peng, Zhiguo Hou, Rongrong Zheng, Yuting Chen, Kai Yin, Zhenggang Zhu

SOX with or without perioperative camrelizumab in locally advanced gastric cancer

More posts featuring Erman Akkus on oncodaily.com

Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.